Monoclonal antibodies to human thymidine kinase to treat cancer
OwnerNathaniel C. Lallatininventor
Life of this patent
Estimating the term…
Abstract
A method of treatment of cancer, viral infections, and the like administers anti-TK1 antibody, constituted as the complete antibody or a fragment thereof. The antibody binds to the surface of cells expressing TK1 thereon. The antibody, with or without another agent bound thereto, may effect complement mediated lysis, antibody-dependent cell-mediated cell cytotoxicity, apoptosis, an immune response by the mammal, a reduction in cellular replication, a combination thereof, or the like for such cells. The antibody may be coupled to an immune response stimulator, a cytotoxin, an enzyme, a combination, or the like to effect the treatment desired.
Claims20
A method of treatment comprising:
- providing an anti-TK1 antibody;
- administering to a mammal the antibody constituted as at least one of the complete antibody and a fragment of the antibody;
- binding, by the antibody, to the surface of first cells expressing TK1 on the surfaces thereof;
- and
- effecting against the first cells, in response to the antibody, at least one of complement mediated lysis, antibody-dependent cell-mediated cell cytotoxicity, apoptosis, an immune response by the mammal, and a reduction in cellular replication.
A method for treating cancer characterized by increased expression of TK1 by cancer cells in a mammal, the method comprising administering to the mammal a therapeutically effective amount of a pharmaceutical composition comprising at least one of an anti-TK1 antibody and a fragment of the anti-TK1 antibody selected to be effective to do at least one of inhibit cellular replication of cancer cells and kill cancer cells.
The method of claim 8, wherein the anti-TK1 monoclonal antibody is the Abnova H00007083-M02 antibody.
A method for diagnosing cancer in a human, the method comprising:
- obtaining a sample of cells from a human subject;
- incubating the sample with at least a fragment of an anti-TK1 antibody;
- detecting an amount of antibody-TK1 complex in the sample;
- quantifying a concentration of TK1 in the sample by comparing the detected amount of antibody-TK1 complex with a standard curve generated using known amounts of TK1;
- and
- diagnosing the presence of cancer in the subject based on the concentration.
A method of treating mammals, the method comprising administering an anti-TK1 monoclonal antibody to target and destroy tumor cells that express TK1 on the surface thereof by introducing a quantity of anti-TK1 antibody into the bloodstream of a mammal to bind to TK1 on the surface of cells, thereby effecting at least one of complement mediated lysis, antibody dependent cell mediated cell cytotoxicity, and apoptosis of the targeted tumor cells.
Dependencies are inferred from the claim text.